BioSig Technologies Reports No Revenue and $20.4 Million Net Loss in Latest Quarter

BioSig Technologies, Inc. reported significant financial changes in its latest 10-Q filing for the quarter ending June 30, 2025. The company recorded no revenue for the three and six months ended June 30, 2025, a decline from $13,000 and $27,000 in the same periods of 2024, respectively. Operating expenses surged to $20.4 million for the quarter, up from $5.3 million year-over-year, primarily due to increased general and administrative costs associated with the acquisition of Streamex Exchange Corporation. The net loss attributable to common shareholders was $20.4 million, compared to a loss of $3.9 million in the prior year.

The company’s balance sheet reflects a substantial increase in total assets, which rose to $109.7 million as of June 30, 2025, compared to $842,000 at the end of 2024. This increase is largely attributed to the acquisition of Streamex, which added $58.7 million in goodwill and $48.6 million in intangible assets. Current liabilities also saw a dramatic rise to $113.2 million, primarily due to the recognition of a derivative liability of $105.5 million related to the exchangeable shares issued in the acquisition.

In terms of strategic developments, BioSig completed the acquisition of Streamex on May 28, 2025, which is expected to enhance its product offerings and expand into digital asset infrastructure. The acquisition is anticipated to provide access to Streamex’s engineering talent and regulatory framework, positioning BioSig for future growth in the blockchain and commodity trading sectors. The company is actively working on the development of a blockchain-based platform for tokenized commodities, with an initial focus on gold-backed financial products.

Operationally, BioSig's employee headcount has increased significantly, reflecting the integration of Streamex and the expansion of its workforce to support new initiatives. The company is also focusing on cost-saving measures to manage its cash burn rate, which included reductions in executive compensation and workforce. As of June 30, 2025, BioSig had cash reserves of $2.8 million, but a working capital deficit of $110 million raises concerns about its liquidity and ability to continue operations without additional financing.

Looking ahead, BioSig anticipates continued operating losses and negative cash flows until its products achieve commercial success. The company is exploring various funding sources, including public or private equity offerings and strategic partnerships, to secure the necessary capital for ongoing operations and development. However, there is no assurance that these efforts will be successful, and the company has expressed substantial doubt about its ability to continue as a going concern without additional financing.